Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DHR
Danaher
Market cap
$121.74B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | DHR | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 63D | 65C | GMAB |
| Benjamin Graham | 69B | 64C | DHR |
| Philip Fisher | 47D | 48D | GMAB |
| Peter Lynch | 22F | 25F | GMAB |
| Joel Greenblatt | 45D | 76B | GMAB |
| Charlie Munger | 54D | 68C | GMAB |
| Terry Smith | 52D | 71C | GMAB |
| Metric | DHR | GMAB |
|---|---|---|
| Market cap | $121.74B | $16.5B |
| P/E (TTM) | 31.1x | 6.2x |
| EV/EBIT | 24.8x | 12.0x |
| ROIC (TTM) | 5.73% | 43.78% |
| Gross margin | 60.68% | 93.88% |
| Net margin | 14.89% | 18.23% |
| Revenue CAGR 5y | -4.43% | -18.45% |
| EPS CAGR 5y | -12.8% | -23.48% |
| Debt / Equity | 0.3x | 0.1x |
| Dividend yield | 0.84% | 0.0% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DHR leads on
GMAB leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.